Cardiac Remodeling in Heart Failure: Role of Pyroptosis and Its Therapeutic Implications

Ruoning Chai1†, Wenjing Xue2†, Shuqing Shi3†, Yu Zhou4, Yihang Du1, Yuan Li4, Qingqiao Song3, Huaqin Wu1* and Yuanhui Hu1*

1 Department of Cardiovascular, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, 2 Department of Clinical Medicine, Beijing University of Chinese Medicine, Beijing, China, 3 Department of Internal Medicine, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, 4 Department of Clinical Medicine, Shaanxi University of Chinese Medicine, Xianyang, China

Pyroptosis is a kind of programmed cell death closely related to inflammation. The pathways that mediate pyroptosis can be divided into the Caspase-1-dependent canonical pathway and the Caspase4/5/11-dependent non-canonical pathway. The most significant difference from other cell death is that pyroptosis rapidly causes rupture of the plasma membrane, cell expansion, dissolution and rupture of the cell membrane, the release of cell contents and a large number of inflammatory factors, and send pro-inflammatory signals to adjacent cells, recruit inflammatory cells and induce inflammatory responses. Cardiac remodeling is the basic mechanism of heart failure (HF) and the core of pathophysiological research on the underlying mechanism. A large number of studies have shown that pyroptosis can cause cardiac fibrosis, cardiac hypertrophy, cardiomyocytes death, myocardial dysfunction, excessive inflammation, and cardiac remodeling. Therefore, targeting pyroptosis has a good prospect in improving cardiac remodeling in HF. In this review, the basic molecular mechanism of pyroptosis is summarized, the relationship between pyroptosis and cardiac remodeling in HF is analyzed in-depth, and the potential therapy of targeting pyroptosis to improve adverse cardiac remodeling in HF is discussed, providing some ideas for improving the study of adverse cardiac remodeling in HF.

Keywords: pyroptosis, cardiac remodeling, cardiac fibrosis, heart failure, inflammation

INTRODUCTION

Heart failure (HF) is a clinical syndrome caused by insufficient heart pumping function and is the terminal stage of cardiovascular diseases, affecting approximately 64.3 million people worldwide (1, 2). In developed countries, the prevalence of known HF is generally estimated at 1% to 2% of the general adult population (3, 4), the study indicated patients with HF had 87%, 73%, 57%, and 35% survival at 1, 2, 5, and 10 years (5), and HF events increased the risk of death by five times. The absolute number of HF patients will continue to increase due to population aging, global population, and improved survival rates after diagnosis, as well as a gradual increase in younger patients (<55 years). North America had the highest hospitalization rate for HF (11/100 person-years) (6), HF remains a serious clinical and public health problem (7–10). Despite significant advances in drug and instrumental treatment of HF over the past two decades, patient outcomes and quality of life remain inadequate, which may be closely related to a focus on symptomatic treatment and a lack of in-depth discussion of pathophysiology (9).
Left ventricular function is an important indicator for evaluating HF and is also a key point in the study of potential mechanisms in pathophysiology (3). The occurrence and progression of HF are closely related to cardiac remodeling, which is characterized by changes in cardiac structure, shape, and function, and cardiomyocytes death is a key step in cardiac remodeling (11, 12). Cell death is the final stage of cell life, including programmed cell death and non-programmed cell death, of which pyroptosis is a type of programmed cell death that accompanies an inflammatory response (13). Pyroptosis is a double-sided sword, on the one hand, moderate pyroptosis can contribute to cellular homeostasis, effectively prevent excessive cell proliferation and protect the host, on the other hand, excessive pyroptosis can cause cardiac fibrosis, myocardial hypertrophy, cardiomyocytes death, myocardial dysfunction, excessive inflammation and promote cardiac remodeling (14). The most significant difference between pyroptosis and other modes of cell death lies in the rapid rupture of the plasma membrane, cell expansion, dissolution and rupture of the cell membrane, the release of cell contents and a large number of inflammatory factors, send pro-inflammatory signals to adjacent cells, recruit inflammatory cells and induce inflammatory responses (14–16). Nowadays, many studies have proved that pyroptosis may be an endogenous regulatory factor of cardiovascular diseases and play an important role in cardiovascular diseases (17).

In this review, the basic molecular mechanism of pyroptosis is summarized, the relationship between pyroptosis and cardiac remodeling HF is analyzed in-depth, and the potential therapy of inhibiting pyroptosis to improve cardiac remodeling HF is discussed, which provides some ideas for improving adverse cardiac remodeling HF from the perspective of pyroptosis.

OVERVIEW OF PYROPTOSIS

Pyroptosis, also known as inflammatory necrosis of cells (18), was first observed by Cookson and Brennan in salmonella-infected macrophages and named pyroptosis (19). When pathogens invade a host cell, pattern recognition receptors (PRRs) are capable of recognizing pathogen-associated molecular patterns (PAMPs) and damage-associated molecules patterns (DAMPs) intracellularly, bind to specific ligands, and combine with other proteins to form inflammasome (15, 20, 21). Meanwhile, the canonical pathway also detects cytoplasmic disturbances, recently coined as homeostasis altering molecular properties (HAMPs), and the recognition of HAMPs is through the detection of molecular processes that perturbs cytoplasmic homeostasis (22, 23). PRRs involved in pyroptosis mainly include nod-like receptors (NLRs) family—NLRP3, NLRP1, NLRP6, NLRP9, NLRC4, PYHIN200 family—Absent in melanoma 2 (AIM2) and TRIM family—Pyrin (24–26). NLRP3 is currently the most famous inflammasome and the noncanonical pathway crosstalks with the canonical pathway via NLRP3 (27). NLRs generally contain three domains: an N-terminal adaptor domain [such as CARD or pyrin domain (PYD)], a central nucleotide-binding domain (NBD), and a C-terminal leucine-rich repeat (LRR) domain. NLRP1 contains two additional domains at its C-terminus, a CARD followed by a function to find domain (FIIND) domain. The LRR domains are used to detect bacterial components, the NBD domain is critical for oligomerization and activation, the N-terminal domain is responsible for CARD recruitment and CARD-CARD interactions as well as for activating Caspase-1. As the activation platform of Caspase, the inflammasome plays an important role in the occurrence of pyroptosis. When cells are subjected to different stimuli, the induced pyroptosis pathway is different, which can be divided into the Caspase-1-dependent canonical pathway and the Caspase4/5/11-dependent non-canonical pathway (28, 29).

The Canonical Pathway of Pyroptosis

When cells are infected by pathogens or sense endogenous danger signals, PRRs interact with PAMPs or DAMPs and activate the apoptosis-associated speck-like protein (ASC) to activate ASC proteins through protein-protein interactions (21, 30). The C-terminal CARD domain of ASC and the N-terminal CARD domain of pro-Caspase-1 combine to recruit active-Caspase-1 (31). The binding complex of PRRs, ASC, and pro-Caspase 1 is termed the inflammasome. On the one hand, Caspase-1 recognizes pro-IL-1β and pro-IL-18, converts them into IL-1β and IL-18, and releases them extracellular to expand the inflammatory response, on the other hand, Caspase-1 shear Gasdermin family protein GSDMD to separate its N- and C- domains, N-terminal fragments are released to the membrane, mediating the formation of cell membrane pores, releasing inflammatory factors and inducing pyroptosis (32). The canonical pathway also utilizes toll-like receptors (TLRs) for priming certain PRRs to enhance immune responses, TLR4 can upregulate NLRP3 (33, 34) and GSDMD (35) to promote pyroptosis via Nek7, GBP5, and NF-kB signaling. NLRC4 can directly interact with pro-Caspase-1 via CARD-CARD to form active-Caspase-1 and induce pyroptosis (36, 37) (Figure 1).

The Non-canonical Pathway of Pyroptosis

In addition to the canonical pathway of pyroptosis, the CARD domain of pro-Caspase 4/5/11 directly interacts with the intracellular lipopolysaccharides (LPS) of Gram-negative bacteria, causing a significant conformational rearrangement of pro-Caspase 4/5/11 (36, 37) and resulting in oligomerization and autoproteolysis. After oligomerization, Caspase 11 auto-proteolyze after D285 with a sequence of MEAD|A to gain full activity in proteolyzing GSDMD (38, 39). However, activated Caspase 4/5/11 has been considered only to recognize GSDMD and cleave at D275 of hGSDMD or D276 of mGSDMD for generating pyroptotic pores (38, 39). Meanwhile, Caspase 4/11 were activated by guanylate-binding proteins 1-4 (38), and Caspase 4/5/11 also crosstalk with NLRP3, both of them can process to pyroptosis. The K⁺ efflux caused by cell membrane pore formation induces activation of the NLRP3/ASC/ Caspase-1 pathway (39, 40). The non-canonical pathway has also been considered to involve mitochondrial dysfunction, such as the release of mitochondrial reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) (39). In addition, Caspase-3 cleaves the Gasdermin family protein GSDME, releasing the
FIGURE 1 | The basic molecular mechanism of pyroptosis. The canonical pathway of pyroptosis, Nod-like receptors protein-3 (NLRP3), NLRP1, NLRP6, NLRP9, absent in melanoma 2 (AIM2), and Pyrin binds to the N-terminal PYD region of the apoptosis-associated speck-like protein (ASC) to activate ASC proteins through protein-protein interactions. The C-terminal CARD domain of ASC and the N-terminal CARD domain of pro-Caspase-1 combine to recruit active-Caspase-1. The binding complex of PRRs, ASC, and pro-Caspase 1 is termed the inflammasome. On the one hand, Caspase-1 recognizes pro-IL-1β and pro-IL-18, converts them into IL-1β and IL-18, and releases them extracellular to expand the inflammatory response, on the other hand, Caspase-1 shears Gasdermin family protein GSDMD to separate its N- and C- domains, N-terminal fragments are released to the membrane, mediating the formation of cell membrane pores, releasing inflammatory factors and inducing pyroptosis. NLRC4 can directly interact with pro-Caspase-1 via CARD-CARD to form active-Caspase-1 and induce pyroptosis. The non-canonical pathway of pyroptosis, Caspase4/5/11 can directly bind to lipopolysaccharide (LPS) in the cytoplasm and initiate pyroptosis following cleavage of GSDMD-induced membrane pore formation and subsequent cell membrane rupture. The K^+ efflux caused by cell membrane pore formation induces activation of the NLRP3/ASC/Caspase-1 pathway. In addition, Caspase-3 cleaves the Gasdermin family protein GSDME, releasing the N-terminal active fragment to the cell membrane, leading to pyroptosis.

The Regulation of NLRP Inflammasome on Pyroptosis

NLRP Inflammasome belongs to the NLRs family which generally contains three domains: an N-terminal adaptor domain [such as CARD or pyrin domain (PYD)], a central nucleotide-binding domain (NBD), and a C-terminal leucine-rich repeat (LRR) domain. NLRP1 contains two additional domains at its C-terminus, a CARD followed by a function to find domain (FIIND) domain. The LRR domains are used to detect bacterial components, the NBD domain is critical for oligomerization and activation, the N-terminal domain is responsible for CARD recruitment and CARD-CARD interactions as well as for activating Caspase-1.

NLRP3

The NLRP3 inflammasome is the best studied and possesses the most complex signaling of all inflammasomes. NLRP3 must first be primed by a cytokine receptor or another PRR (41). When NLRP3 is knocked out in mice or antagonized, there is a significant reduction of pyroptosis. Interestingly, lysosomal membrane damage results in K^+ efflux and the release of lysosomal protease cathepsin B, both of which initiate NLRP3 inflammasome activation (42). The protein NIMA-related kinase 7 (NEK7), which participates by regulating NLRP3 inflammasome formation following potassium release and preventing inflammasome formation during mitotic division.
stages of the cell cycle, is a crucial player during NLRP3 activation (43, 44). Co-crystal structures show that NEK7 directly binds to two neighboring NLRP3 subunits (44). Knockdown of RB4 alleviated ischemia-hypoxia-induced activation of NLRP3 inflammasome signaling and pyroptosis in cardiomyocytes (45). After activation, the NLRP3 receptor recruits the ASC by PYD-PYD interaction, assembling the NLRP3 inflammasome. NLRP3 crosstalks with other innate immune pathways (46, 47), indicating that the inhibition of the NLRP3 could have a prospect effect on inflammatory responses. Therefore, NLRP3 is a hopeful drug target for patients with inflammatory diseases (48).

NLRP1
NLRP1 was the first discovered NLR family member that was discovered to be involved in the formation of an inflammasome complex. The NLRP1 possesses a C-terminal CARD domain and an N-terminal pyrin domain so that it can activate pro-Caspase 1 without ASC oligomerization, leading to IL-1β secretion (49, 50). It is coded by a single gene in humans with three homologs NLRP1a, b, and c in mice (51). In terms of human disease, the NLRP1 inflammasome is genetically associated with several other autoimmune diseases (52). Interestingly, inhibitors of dipeptidyl peptidases 8 and 9 (DPP8/9) can selectively activate NLRP1 and its related protein CARD8 in both mouse and human lymphocytes (53). The activation of the NLRP1 inflammasome can promote the secretion of high mobility group protein B1 (HMGB1), which stimulates inflammatory responses by modulating both the innate and the adaptive immune responses (54).

NLRC4
NLRC4 plays an important role in protection against certain Gram-negative bacteria with type III or type IV secretion systems (55). NLRC4 combines with NAIPs (NLR family apoptosis inhibitory proteins) to form complexes and activates NLRC4 by binding to pathogenic proteins from flagellin or apoptosis inhibitory proteins) to form complexes and activates NLRC4 by binding to pathogenic proteins from flagellin or type III/IV secretion systems. NLRC4 oligomerizes and directly interacts with pro-Caspase 1 via a CARD-CARD interaction, bypassing the participation of ASC, when the NLRC4 is activated (55). There are several gain-of-function mutations in NLRC4, which have been shown to result in the development of autoimmune diseases (56).

ROLE OF PYROPTOSIS IN CARDIAC REMODELING

Role of Pyroptosis in Cardiac Fibrosis
Cardiac fibrosis, the expansion of the cardiac interstitium due to a net accumulation of extracellular matrix (ECM) proteins, occurs primarily in cardiac fibroblasts and accompanies most cardiac pathologic conditions (60). Activated fibroblasts contribute to the regulation of matrix remodeling by producing proteases, such as matrix metalloproteinases (MMPs). During mild injury, extracellular matrix components are temporarily accumulated and quickly eliminated, promoting the recovery of normal tissue structure (61, 62), however, when damage is severe, extracellular matrix components continue to accumulate, leading to structural destruction, organ dysfunction, and ultimately organ failure (63). Cardiac fibrosis has a dual role, although, in most myocardial diseases, the extent of cardiac fibrosis predicts adverse outcomes, in myocardial infarction, reparative fibrosis performs an important repair function, preventing heart rupture (60). Cardiac fibrosis is an important manifestation of cardiac remodeling. It has been found in various cardiovascular diseases that cardiac fibrosis is closely related to pyroptosis, which has an important influence on the occurrence and development of HF.

In a mouse model of HF with transverse aortic constriction (TAC), the content of NLRP3 increased and the degree of myocardial fibrosis increased (64–66). Immunofluorescence was applied to determine the cellular localization of NLRP3 protein in cardiac tissue (67). NLRP3 inflammasome activation mainly occurs in cardiac fibroblasts during myocardial remodeling and repair (68), activates IL-1β release and pyroptosis in cardiac fibroblasts after myocardial infarction (MI) (69). A significant increase in expression of pyroptosis and MMP9 in cardiac fibrosis in diabetes (33, 70). Cardiac dysfunction, cardiac fibrosis (TGF-β1, collagen I, and collagen III), pyroptosis (Caspase-1, IL-1β, and GSDMD) were found in diabetic rats (71). Inhibition of Caspase-1 reduced the occurrence of cardiac fibrosis in diabetic cardiomyopathy and improved cardiac function via regulation of miR-135b (71). The proinflammatory cytokines released by pyroptosis activate fibroblasts and promote tissue fibrosis (63, 72). IL-1β and IL-18 promote Ca2+ efflux of the sarcoplasmic reticulum, induces myocardial interstitial fibrosis, activates TNF-α release, and TNF-α reacts on Caspase-1, forming an inflammatory cascade loop and promoting the progression of HF (73, 74).

Activation of the NLRP3 inflammasome was observed in LPS-stimulated cardiac fibroblasts and myofibroblasts, suggesting that the NLRP3 inflammasome and pyroptosis may contribute to myocardial dysfunction upon pyroptosis (16, 73).

Role of Pyroptosis in Myocardial Hypertrophy
Myocardial hypertrophy is divided into physiological and pathological. Physiological cardiac hypertrophy is of great significance for maintaining cardiac efficiency, however, hypertrophic cardiomyopathy, long-term uncontrolled systolic hypertension, and continuous overload pressure from cardiac
valve stenosis can promote cardiac remodeling and lead to HF (75, 76).

Factors related to pyroptosis play an important role in myocardial hypertrophy. There was a report that hyperactivated NLRP3 inflammasome with pyroptosis of cardiomyocytes were presented in the myocardial tissues of dilated cardiomyopathy patients, which were negatively correlated with cardiac function (77). In vitro and in vivo models of cardiac hypertrophy, the expression levels of pyroptosis-related factors were significantly increased (66), downregulation of Caspase-1 and IL-1β expression by Caspase-1 inhibitors attenuates angiotensin II (Ang II) -induced cardiac hypertrophy (78). A recent study indicated that NLRP3 levels in C57/BL6 mice with chronic pressure overload-induced by TAC were significantly increased and were involved in the production of inflammatory mediators and fibrosis factors, leading to myocardial fibrosis, myocardial hypertrophy, and impaired cardiac function (64). Under pressure overload, S-nitrosylation of muscle LIM protein (MLP) increased the complex formation between toll-like receptor 3 (TLR3) and receptor-interacting protein kinase 3 (RIP3), inducing NLRP3 inflammasome activation, and promoting the development of myocardial hypertrophy. Pharmacologic blockade or RNA interference of NLRP3 and inhibition of IL-1β could reduce pressure overload-induced myocardial hypertrophy (79). Meanwhile, IL-18 expression was significantly increased during pressure overload in rabbit models with TAC (80). There is good evidence that the heart weight/body weight ratio was significantly increased in the diabetic cardiomyopathy group compared to the control (33). Elmadbouh I and Singla DK found that diabetic cardiomyopathy involves sterile inflammation and causes the upregulation of NLRP3-Nek7-GBP5 inflammasome complex, which finally initiates Caspase-1-dependent pyroptosis in diabetic cardiomyopathy. Inflammation-induced pyroptosis has adverse effects on diabetic cardiac remodeling, endothelial progenitor cells, neovascularization, and cardiac function (33). Meanwhile, silica nanoparticles (SiNPs) exposure is correlated with adverse cardiovascular effects, literature suggested SiNPs could trigger pyroptosis and cardiac hypertrophy via ROS/NLRP3/Caspase-1 signaling pathway (81). miR-133A-3p could target IKKs to inhibit pyroptosis, alleviate myocardial hypertrophy, and protect cardiac function (82). In H9C2 cardiomyocytes, NF-κB, NLRP3, and receptor of advanced glycation endproducts (RAGE) induced hypertrophy through the RAGE-NF-κB- NLRP3- IL-1β signaling pathway (83).

Role of Pyroptosis in Excessive Inflammation
Cardiomyocyte necrosis and inflammation play key roles in the pathophysiology of cardiovascular diseases. The inflammatory response is mainly to repair the heart, but the excessive inflammatory response will lead to cardiac dysfunction, adverse cardiac remodeling, and HF (14).

NLRP3 inflammasome contributes a lot to sterile inflammatory response and pyroptosis in ischemia/reperfusion (I/R) injury (67). Inflammation triggered by pyroptosis (NLRP3)-related pyroptosis of cardiac fibroblasts (CFs) resulted in cardiomyocytes death and myocardial dysfunction (67). It was found that NLRP3 and other inflammatory factors were generally elevated in myocardial cells after MI, and the subsequent response was mainly generated by the activation and release of inflammatory factors (84). Meanwhile, cell fragments and metabolites act as DAMPs to activate inflammasome and membrane P2X7 receptor channels, causing K+ efflux, activating NLRP3, the activated NLRP3 to recruit ASC and pro-Caspase-1, activates Caspase-1, Caspase-1 splines pro-IL-1β, and other pro-inflammatory cytokines into active mature bodies that recruit and activate other immune cells and induce the synthesis of chemokines, inflammatory cytokines, and adhesion factors, further amplifying the inflammatory response (17, 85–88). Cardiomyocyte H/R induced the release of the inflammatory factor IL-18, which is associated with pyroptosis, in the cell culture supernatant, but there was no IL-1β release. IL-18 further amplifies the inflammatory cascade by inducing additional cytokines, adhesion molecules, and chemokines. Neutralization of IL-18 significantly attenuates I/R-induced tissue damage in vivo. Streptozotocin (STZ)-induced diabetic cardiomyopathy significantly increased inflammasome formation (TLR4, NLRP3, Nek7, and GBP5), which induced the occurrence of pyroptosis, accompanied by the increased of inflammatory cytokines (IL-6 and TNF-α), MMP9, infiltration of monocytes (CD14), macrophage (iNOS), and dendritic cells (CD11b and CD11c). Moreover, significant endothelial progenitor cells (EPCs) dysfunction (c-Kit/FLk-1, CD31), adverse cardiac remodeling, and reduction in left ventricular (LV) heart function were observed (33). BMP-7 reduced inflammation and improved adverse myocardial remodeling, hypertrophy as well as interstitial and vascular fibrosis (33).

The expression of IL-1β was mainly derived from fibroblasts and IL-1β was not significantly altered in cardiomyocytes under oxidative stress conditions, cardiomyocyte pyroptosis, and release of the proinflammatory cytokine IL-18 may activate cardiac fibroblasts to induce the secondary production of cytokines (89). Caspase-1 is an important regulator of the inflammatory response, activated Caspase-1 can trigger pyroptosis, and the release of pro-inflammatory cytokines IL-1β and IL-18 can cause the amplification of inflammatory cascade, resulting in endothelial dysfunction, and then produce or increase the development of myocardial fibrosis. ROS produced by oxidative stress can activate the NLRP3 inflammasome, leading to Caspase-1 activation and IL-1β secretion (90–92). When the ROS system of cardiomyocytes is activated, the accumulated ROS and Ca2+ are released into the cytoplasm, and the mitochondrial membrane potential changes, resulting in pyroptosis. Pirfenidone can regulate the ROS-dependent NLRP3- IL-1β signaling pathway by inhibiting NLRP3, improving left ventricular hypertrophy and myocardial fibrosis in rats with TAC (93).

Role of Pyroptosis in Cardiomyocytes Death and Myocardial Dysfunction
Pyroptosis directly leads to the death of cardiomyocytes, which reduces the number of effective cardiomyocytes, thereby
 affecting the systolic and diastolic functions of the myocardium and promoting cardiac remodeling in HF. In adult mouse cardiomyocytes, the absence of GSDMD markedly blocked H/R-induced cardiomyocyte pyroptosis, which is associated with N-terminal fragment cleavage release (94, 95). Immunoblot analysis revealed significantly increased levels of GSDMD and GSDMD-N after H/R in adult mouse cardiomyocytes in a time-dependent manner, bring with large numbers of balloon-shaped vesicles and accumulation of propidium iodide (PI), which are typical characteristics of pyroptosis, as well as exhibited decreased ATP levels and the loss of cell membrane integrity. The mouse myocardial I/R injury model showed that GSDMD deficiency significantly reduced I/R-induced myocardial infarct size. Serum GSDMD levels were also significantly higher after percutaneous coronary intervention in patients with ST-segment–elevation myocardial infarction than in age-matched stable coronary artery disease patients (89). Moreover, trimetazidine and silencing PVT1 could alleviate myocardial I/R damage through suppressing GSDMD-mediated pyroptosis in vitro and in vitro, involved TLR4/MyD88/NF-κB/NLRP3 inflammasome pathway, improved cardiac fibrosis, inflammatory cytokines, and cardiac function (94, 96). NLRP3

| Drugs          | Models               | Mechanism                                                                 | Effects                                                                                     | Ref  |
|----------------|----------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------|
| Rosuvastatin   | CME rats             | Rosuvastatin decreased the expression of NLRP3, Caspase-1, IL-1β, GSDMD;   | Pyroptosis (NLRP3, Caspase-1, IL-1β, GSDMD); Cardiac fibrosis, Cardiac systolic function, Cardiac remodeling | (105, 106) |
| Metformin      | I/R                  | Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway | Pyroptosis (NLRP3, IL-1β); Cardiac fibrosis, Inflammation (TNF-α, IL-6); Myocardial infarct size, Cardiomyocyte activity (LDH) | (107) |
| Trimebazidine  | I/R                  | Trimebazidine/Emodin alleviated pyroptosis induced by myocardial I/R injury through the TLR4/MyD88/NF-κB/NLRP3 inflammasome pathway | TLR4, MyD88, phospho-NF-κB p65, the NLRP3 inflammasome; Infarct size; Viability of H9c2 cardiomyocytes | (94, 108) |
| Liraglutide    | Hypoxia H9C2         | Liraglutide alleviated pyroptosis mediated by NLRP3 inflammasome by down-regulating the SIRT1/NOX4/ROS pathway | Pyroptosis (NLRP3, Caspase-1 p20, GSDMD-N); Cardiomyocyte activity (LDH) | (109) |
| Pinocembrin    | DOX-induced cardiotoxicity | Pinocembrin inhibited DOX-induced cardiomyocyte pyroptosis via activating Nrf2/Sirt3 signal pathway | Pyroptosis (IL-1β, IL-18); Cardiac fibrosis, Cardiac function (LVEF, LVFS, LDH, CK-MB) | (111) |
| Pyrroloquinone quinone | DCM | Pyrroloquinone quinone improved DCM in diabetic mice by inhibiting NF-κB/NLRP3 inflammasome-mediated cell pyroptosis. | Pyroptosis (NLRP3, Caspase-1, IL-1β, IL-18); Cardiac fibrosis (collagen I and TGF-β1); Myocardial hypertrophy (ANP and BNP) | (112) |
| Artemisinin    | I/R                  | Artemisinin inhibited cardiac autophagy, improved mitochondrial electron transport chain activity, decreased activation of NLRP3 inflammasome. | Pyroptosis (NLRP3, ASC, cleaved Caspase-1, IL-1β); Infarct size and CK-MB, LDH; Cardiomyocyte autophagy | (113) |
| Ranolazine     | DCM                  | miR-135b directly bound to Caspase-1 | Pyroptosis (Caspase-1, IL-1β, GSDMD); Cardiac Fibrosis (TGF-β1, collagen I and collagen III); Cardiac function | (71) |
| Sevoflurane    | I/R patients with myocardial ischemia | Sevoflurane inhibited the expression of IL-1β, IL-18, and GSDMD by inhibiting the P2X7-NLRP3 signaling pathway | Pyroptosis (NLRP3, Caspase-1, GSDMD, IL-1β, IL-18); Cardiac injury (CK, CK-MB, LDH, MDA, SOD); Inflammation (CD11b) | (114) |
| Piperazine ferulate | I/R | Piperazine ferulate can suppress the I/R-triggered NLRP3 inflammasome activation and pyroptosis | Pyroptosis (NLRP3, Caspase-1, GSDMD, IL-1β, ASC); Cardiac function (LVEF, LVFS); mitral early diastolic flow velocity/late diastolic flow velocity, infarction size | (113) |
| Iglutamid      | I/R                  | Iglutamid protected cardiomyocytes by reducing the cascade of inflammation in the heart by inhibiting cardiac fibroblast pyroptosis via the COX2/NLRP3 signaling pathway. | Pyroptosis (NLRP3, Caspase-1, GSDMD, IL-1β, IL-18); Inflammatory response (IL-6, TNF-α) | (67) |
| Syringaresinol | Sepsis mouse         | Syringaresinol ameliorated sepsis-induced cardiac dysfunction via the ER/SIRT1/NLR3/GSDMD pathway. | Proinflammatory cytokines; Cardiac function | (99) |

CME, coronary microembolization; I/R, myocardial reperfusion; ROS, reactive oxygen species; LDH, lactate dehydrogenase; TNF-α, tumor necrosis factor α; NF-κB, nuclear-factor-κB; TLR4, toll-like receptors 4; SIRT1, Sir2 homolog 1; NOX4, NADPH oxidase 4; Dox, doxorubicin; CK-MB, creatine kinase-MB; DCM, diabetic cardiomyopathy; cTnl, cardiac troponin I; EF, ejection fraction; FS, fractional shortening; CO, cardiac output; SV, stroke volume; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; MDA, malondialdehyde; SOD, superoxide dismutase; ER, estrogen receptor.
| Potential molecules | Models | Mechanism | Effects | Refs |
|---------------------|--------|-----------|---------|------|
| MLK3 miR-351        | TAC    | MLK3 mainly regulates NF-κB/NLRP3 signaling pathway-mediated inflammation and that pyroptosis causes myocardial fibrosis in the early stages of CHF | Pyroptosis ↓; Cardiac hypertrophy ↓; Cardiac Fibrosis ↓; Cardiac function ↑ | (65) |
| LncRNA PVT1         | H/R-treated H9C2 cells | Silencing PVT1 could alleviate myocardial I/R damage by suppressing GSDMD-mediated pyroptosis | Pyroptosis (GSDMD-N ↓); Cardiac Fibrosis ↓; Inflammatory cytokines ↓; Cardiac function (α-MHC and β-MHC) ↑ | (96) |
| NOX1, NOX4, Drp1    | DCM    | Dox enhanced expressions of NOX1 and NOX4 and induced mitochondrial fission through dynamin-related protein 1 activation, leading to NLRP3 inflammasome-mediated pyroptosis in cardiomyocytes via Caspase-1-dependent manner. | Pyroptosis (NLRP3, ASC, Caspase-1, IL-1β, IL-18) ↓ | (77) |
| BMP-7               | DCM    | BMP-7 activated the TLR4-NLRP3 inflammasome complex by signaling Nek7/GBP5. | Pyroptosis (Caspase-1, IL-1β, IL-18) ↓; Cardiac fibrosis (MMP-9 ↓; Cardiac hypertrophy and dilatation); Inflammasome formation (TLR4-NLRP3); Inflammatory cytokines (IL-6, TNF-α); Inflammatory cells (CD14, NOX, CD11b, CD11c); Adverse cardiac remodeling; EPC markers and neovascularization (c-KIT/Flik-1 and CD31/α-SM actin) ↑; Cardiac function ↑ | (33) |
| Becn1               | I/R    | Becn1 overexpression suppressed Caspase-4 inflammasome activation and pyroptosis by enhancing autophagic flux. | Pyroptosis (Caspase-4, IL-1β, GSDMD) ↓; Inflammation (F4/80+ macrophages and CD11b+ neutrophils infiltration in the heart) ↓; Autophagic flux (Becn1, LC3-II/LC3I) ↑; Myocardial infarct size (LDH, CK) ↓ | (97) |
| sRAGE               | I/R    | sRAGE protected the heart from pyroptosis by inhibiting the NF-κB pathway during myocardial ischemia-reperfusion. | Pyroptosis (NLRP3, Caspase-1, GSDMD, IL-1β, IL-18) ↓; Cardiac function (the movement of the left ventricle anterior wall, CO, SV, EF, FS) ↑; Myocardial infarct size (cTnI) ↓ | (119) |
| METTL3              | I/R    | METTL3 promoted DGC8 binding to pri-miR-143-3p through m6A modification, thus enhancing miR-143-3p expression to inhibit PRKCE transcription and further aggravating cardiomyocyte pyroptosis and MI/R injury. | Pyroptosis (NLRP2, Caspase-1, GSDMD-N, IL-1β, IL-18) ↓; Myocardial injury ↓ | (119) |
| RBP4                | AMI    | RBP4 interacted directly with NLRP3 in cardiomyocytes, promoted the precursor cleavage of Caspase-1, and subsequently induced GSDMD dependent pyroptosis. | Pyroptosis (GSDMD, ASC, pro-Caspase-1, Caspase-1-p10, GSDMD, cleaved GSDMD, and IL-18) ↓; Hypertrophic markers (ANP, BNP, and MHC7) ↓; Myocardial infarct size ↓; Adverse cardiac remodeling (left ventricular internal dimension and left ventricular volume) ↓; Cardiac function (EF, FS) ↑ | (45) |
| IRF2                | MI     | IRF2 is directly bound to the GSDMD promoter to drive GSDMD transcription and promote pyroptosis and IRF2 expression may be regulated via the HIF-1 signaling pathway. | Pyroptosis (Cleaved caspase-1, IL-1β, IL-18, GSDMD-N, GSDMD) ↓; Cardiac function (EF, FS) ↑ | (65) |
| LncRNA KLF3-AS1     | MI     | LncRNA KLF3-AS1 in exosomes secreted from hMSCs by acting as a ceRNA to sponge miR-138-5p can regulate Sirt1 to inhibit pyroptosis and attenuate MI progression. | Apoptosis and pyroptosis ↓; Myocardial infarct size ↓ | (64) |
| miR-762             | I/R    | Delivery of exogenous miRNA-762 before transplantation significantly increased the post-transplant survival of stem cells and also significantly ameliorated cardiac fibrosis and heart functions following I/R injury. | Pyroptosis (Caspase-1, Caspase-11, Caspase-1, GSDMD, IL-1β) ↓; Cardiac function ↑ | (120) |

TAC, transverse aortic constriction; MLK3, mixed lineage kinase 3; I/R, myocardial reperfusion; H/R, hypoxia/reoxygenation; MHC, myosin heavy chain; RBP4, retinol-binding protein 4; BMP-7, bone morphogenetic protein-7; MMP-9, matrix-metalloproteinase-9; TNF-α, tumor necrosis factor α; TLR4, toll-like receptor-4; sRAGE, soluble receptor for advanced glycation end-products; cTnl, cardiac troponin I; EF, ejection fraction; FS, fractional shortening; CO, cardiac output; SV, stroke volume; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; IRF2, Interferon regulatory factor 2; HIF-1, hypoxia inducible factor 1; ER, estrogen receptor; METTL3, methyltransferase-like protein 3; PRKCE, protein kinase C epsilon; Dox, doxorubicin; NOX, oxidase.
markedly promotes pyroptosis in the progression of AMI, knockdown of NLRP3 attenuated cardiomyocyte pyroptosis and significantly decreased the infarct size, as evidenced by decreased expression levels of ASC, pro-Caspase-1, Caspase-1-p10, GSDMD, cleaved GSDMD, and IL-18 (45). Becn1-driven autophagy is a protective response in the heart during I/R, Becn1 overexpression suppressed Caspase-4 inflammasome activation and pyroptosis, alleviated microvascular damage, reduced infarct size, and mitigated cardiac inflammation and cell death (97). The recent research showed that activation of SIRT1 by inhibition of miR-29a inhibited oxidative stress, pyroptosis and protect I/R injury (98, 99). It has been found that pyroptosis participated in the pathogenesis of sepsis-induced myocardial injury which was associated with the XIST/miR-150-5p/c-Fos axis and ER/SIRT1/NLRP3/GSDMD pathway (99, 100).

Echocardiogram data suggests impaired LV function in diabetic cardiomyopathy, diabetic cardiac systolic and diastolic dysfunction can be preserved by inhibiting pyroptosis proteins (33), CD74 ablation protects against Type 2 diabetes-induced cardiac remodeling and contractile dysfunction through NLRP3/pyroptosis-mediated regulation of ferroptosis (101). IL-1β released by pyroptosis stimulates the synthesis of inducible nitric oxide synthase (iNOS), leading to cell death and cardiac remodeling leading to HF (74, 102). In the progression of HF, the activation of the NLRP3 inflammasome leads to the release of IL-1β, which can induce Ca^2+ efflux in the myocardial plasma reticulum, directly affecting the excitation-contraction coupling of the myocardium, and impairing the systolic function of the myocardium (74). It was found that the amount of ASC, NLRP3, and Caspase-1 in myocardial cells at the edge of AMI increased significantly with time, and the level of NLRP3 in myocardial fibroblasts in ischemic myocardium increased significantly, inhibition of NLRP3 activation could reduce the size of MI and preserve the function of myocardial after infarction (85).

**POTENTIAL CLINICAL APPLICATIONS OF PYROPTOSIS TO AMELIORATE ADVERSE CARDIAC REMODELING IN HF**

The improvement of cardiac remodeling plays an important role in maintaining cardiac function and improving patients’ quality of life. At present, there are many inhibitors targeting factors related to the pyroptosis pathway, and these studies provide a feasible way to better solve the problem of pyroptosis to improve cardiac remodeling in HF. Although many inhibitors of pyroptosis-related molecules have been studied (20, 103, 104), there is still a certain gap between them and clinical use. For this reason, we reviewed some common clinical drugs and effective ingredients of natural drugs targeting pyroptosis and put forward some possible targeting molecules to provide readers with certain ideas.

**Therapy for Improving Cardiac Remodeling by Drugs on Pyroptosis**

MCC950 inhibited inflammation in early myocardial infarction, reduced cardiac fibrosis, and protected cardiac function (105), combined with Rosuvastatin (RVS), MCC950 inhibited the expression of NLRP3, Caspase-1, interleukin-1β, and Gadermin D n-terminal domains, and decreased serum lactate dehydrogenase (LDH) level, improved cardiac systolic function and myocardial fibrosis in mice (106). Metformin inhibited the activation of TNF-α, IL-6, IL-1β, and NLRP3 inflammasome, reduced the size of MI and myocardial fibrosis, enhanced the activity of myocardial cells, reduced the activity of LDH, inhibited pyroptosis and inflammation (107). Trimetazidine (TMZ) and Emocin increased the viability of H9c2 cardiomyocytes subjected to H/R treatment and reduced the infarct size in vivo as well as alleviated pyroptosis induced by myocardial I/R injury through the TLR4/MyD88/IL-1β/NLRP3 inflammasome pathway. Therefore, TMZ represents an alternative treatment for myocardial I/R injury (94, 108). Liraglutide alleviated pyroptosis mediated by NLRP3 inflammasome by down-regulating the SIRT1/NOX4/Ros pathway in H9c2 cells (109). Artemisinin and Triptolide have protective effects on myocardial function, which is related to the reduction of factors involved in pyroptosis (64, 110). It was shown that pinocembrin can inhibit pyroptosis by activation of Nrf2/Sirt3 signaling pathway, LVEF, LVFS, LVIDd, LVID, and myocardial fibrosis were improved, and the expressions of LDH, CK-MB, IL-1β, and IL-18 were reduced (111). Pyrroloquinoline quinone inhibited ROS and NF-kB activation inhibited NLRP3 inflammasome and Caspase-1, IL-1β and IL-18 expression, and improved myocardial hypertrophy and cardiac fibrosis (112). Ranolazine treatment of diabetic cardiac fibrosis inhibited pyroptosis and collagen deposition by upregulating miR-135b (71). Syringaresinol (SYR) improved cardiac function and alleviated myocardial injury in sepsis-induced cardiac dysfunction mouse via the estrogen receptor (ER)/SIRT1/NLRP3/GSDMD pathway (99). Irisin protected cardiac function by inhibiting NLRP3 and ameliorating cardiomyocyte hypertrophy induced by pyroptosis (66). Piperazine ferulate can suppress the I/R-triggered NLRP3 inflammasome activation and pyroptosis (113). Sevoflurane decreased heart-type fatty acid-binding protein (H-FABP), ischemia modified albumin (IMA), IL-1β, and IL-18 in serum, and alleviated myocardial injury in patients with myocardial ischemia (114). Sevoflurane reduced the H/R rats’ injury of cardiomyocytes and protected the cardiac function by regulating inflammatory reaction and pyroptosis by inhibiting the P2X7-NLRP3 signaling pathway (114). These drugs interfere with pyroptosis and improve cardiac remodeling from various mechanisms, which has certain practical significance (Table 1).

**Therapy for Improving Cardiac Remodeling by Potential Molecules on pyroptosis**

Mixed lineage kinase 3 (MLK3) mainly regulates NF-kB/NLRP3 signaling pathway-mediated inflammation and that pyroptosis causes myocardial fibrosis in the early stages of CHF (65). Knockdown of retinol-binding protein 4 (RBP4) in heart attenuates cardiac pyroptosis in AMI via interaction with NLRP3, hypertrophic markers (atrial natriuretic peptide, brain natriuretic peptide, and myosin heavy chain 7) were decreased in the left ventricular myocardium of RBP4 knockdown
FIGURE 2 | Role of pyroptosis in cardiac remodeling. Pyroptosis causes cardiac fibrosis, cardiac hypertrophy, cardiomyocytes death, myocardial dysfunction, excessive inflammation, and cardiac remodeling in heart failure.

mouse, and echocardiography demonstrated that the left ventricular internal dimension and left ventricular volume were also decreased by inhibition of RBP4, indicating attenuated adverse cardiac remodeling. Importantly, knockdown of RBP4 significantly improved AMI-induced decrease of left ventricular ejection fraction and fractional shortening (45). Meanwhile, bone morphogenetic protein-7 (BMP-7) can inhibit the NLRP3 inflammasome complex and their activator Nek7-GBP5, and the subsequent cascade of pyroptosis in diabetic cardiomyopathy, attenuate inflammatory infiltrated dendritic and M1 macrophages, reducing inflammation and adverse cardiac remodeling through enhanced neovascularization following BMP-7 treatment while improving heart function. BMP-7 attenuated inflammation-induced pyroptosis, adverse cardiac remodeling, and improved heart function via the TLR4-NLRP3 inflammasome complex activated by novel signaling Nek7/GBP5 (33). Becn1 overexpression increased ischemia-reperfusion mouse survival and decreased the levels of serum LDH and CK. Becn1 attenuated F4/80+ macrophages and CD11b+ neutrophils infiltration in the heart (97). Meanwhile, myocardial fibrosis was markedly ameliorated, the collagen was decreased through suppressing GSDMD-mediated pyroptosis when PVT1 knockdown (96). miR-135b can alleviate the fibrosis of cardiac fibroblasts, as well as cardiac fibroblast pyroptosis, which can be inhibited via miR-135b that is directly bound to Caspase-1 (71). LncRNA KLF3-AS1 in exosomes secreted from hMSCs by acting as a ceRNA to sponge miR-138-5p can regulate Sirt1 to inhibit pyroptosis and attenuate MI progression (84). Interferon regulatory factor 2 (IRF2) is directly bound to the GSDMD promoter to drive GSDMD transcription and promote pyroptosis and IRF2 expression may be regulated via the HIF-1 signaling pathway (95). Aldehyde dehydrogenase 2 (ALDH2) has been proven to protect the heart and brain against regional I/R injury, in which the protective role is related to the inhibition of pyroptosis. ALDH2 activator N- (1,3-benzodioxol-5-ylmethyl)-2,6-dichloro-benzamide (Alda-1) would improve post-resuscitation cardiac and neurological outcomes in a clinically relevant swine model of cardiac arrest and resuscitation (115). Silencing CMKLR1 could inhibit the expression of activated Caspase-1 and IL-1β, and reduce the occurrence of pyroptosis (116). Resolvins D2 (RvD2), an innate inflammatory suppressor produced by ω3 polyunsaturated fatty acids, has been found to promote NLRP3 degradation through autophagy. IL-1β secretion is reduced in the presence of exogenous RvD2 in vivo and in vitro, which may be a potential therapeutic target for inflammasome (117). There are reports that soluble receptors for advanced glycation end-products (sRAGE) would not only improve cardiac function and diminish the infarction size but also reduce the occurrence of apoptosis, necrosis, and pyroptosis in I/R-treated myocardium. Meanwhile, sRAGE also reduced the levels of pyroptosis-related proteins in cardiomyocytes, such as NLRP3, GSDMD-NT, IL-1β, and IL-18, which were related to the NF-κB pathway (118). These molecules can improve cardiac remodeling by targeting pyroptosis in various pathways or directly, which has certain research value (Table 2).

Interestingly, hydrogen improved cardiac function and reduced the area of cardiac fibrosis by inhibiting NLRP3-mediated pyroptosis, and it has been demonstrated in vitro that hydrogen alleviated cardiomyocyte damage induced by hypoxia and myocardial fibroblast migration and activation induced by Ang II (121). As an important regulator of IL-1β production and subsequent pyroptosis, delivery of exogenous miRNA-762 before transplantation significantly increased the post-transplant survival of stem cells and also significantly ameliorated cardiac fibrosis and heart functions following I/R injury (120). Mesenchymal stem cells (MSCs), derived from bone marrow, placenta, adipose, or other tissues, significantly alleviated cardiac arrest cardiac injuries in swine, in which the protective effects were related to the inhibition of cell pyroptosis and ferroptosis (122).

CONCLUDING REMARKS AND PERSPECTIVES

Adverse cardiac remodeling is a decisive factor in the progression of clinical HF; pyroptosis is involved in various stages of cardiac fibrosis, cardiac hypertrophy, cardiomyocytes death,
myocardial dysfunction, and excessive inflammation, and these factors often overlap to promote cardiac remodeling in HF (123) (Figure 2) Many targeted inhibitors have been developed for pyroptosis, and there are also relevant clinical drugs that can inhibit pyroptosis and improve cardiac remodeling, however, it is undeniable that studies focus on NLRP3 and Caspase-1 inhibition, while there are few studies on another inflammasome (27, 72). Research on improving cardiac remodeling in HF from the perspective of pyroptosis has a good prospect, however, current studies mostly focus on improving the protein indexes and pathological observation related to pyroptosis and cardiac remodeling, and lack of in-depth molecular interaction mechanism, and the theoretical mechanism is not clear, so it is difficult to achieve clinical transformation of research results. In-depth discussion of the molecular interaction mechanism and targeting another inflammasome to improve cardiac remodeling will become our focus in the future.

REFERENCES

1. Global, Regional, and National Incidence. Prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. (2018) 392:1789–858.

2. Baman JR, Ahmad FS. Heart Failure. JAMA. (2020) 324:1015. doi: 10.1001/jama.2020.13310

3. Groenewegen A, Rutten FH, Moerder A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. (2020) 22:1342–56. doi: 10.1002/ejhf.1858

4. Sahle BW, Owen AJ, Mutowo MP, Krum H, Reid CM. Prevalence of heart failure in australia: a systematic review. BMC Cardiovasc Disord. (2016) 16:32. doi: 10.1186/s12872-016-0208-4

5. Jones NR, Roodfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. (2019) 21:1306–25. doi: 10.1002/ejhf.1594

6. Kristensen SL, Martinez F, Indoff PS, Arulogun JI, Boysof S, et al. Geographic variations in the paradigm-HF heart failure trial. Eur Heart J. (2017) 37:3167–74. doi: 10.1093/eurheartj/ejh226

7. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. (2015) 372:1333–41. doi: 10.1056/NEJMoa1406656

8. Tromp J, Ferreira JP, Janwanshansthaporn S, Shah M, Greenberg B, Zannad F, et al. Heart failure around the world. Eur J Heart Fail. (2019) 21:1187–96. doi: 10.1002/ejhf.1585

9. Tromp J, Teng TH, Tay WT, Hung CL, Narasimhan C, Shimizu W, et al. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. (2019) 21:23–36. doi: 10.1002/ejhf.1227

10. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation. (2019) 139:e56–e528. doi: 10.1161/CIR.0000000000007069

11. Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. Jama. (2020) 324:488–504. doi: 10.1001/jama.2020.10262

12. Uriel N, Sayer A, Annamalai S, Kapur NK, Burkhoff D. Mechanical unloading in heart failure. J Am Coll Cardiol. (2018) 72:569–80. doi: 10.1016/j.jacc.2018.05.038

13. Tang D, Kang R, Berghé TV, Vandenabeele P, Kroemer G, the molecular machinery of regulated cell death. Cell Res. (2019) 29. doi: 10.1038/s41422-019-0164-5

14. Li N, Qi Z, Wang Y, Yang X, Yan Z, Li M, et al. Pyroptosis: A New Regulating Mechanism in Cardiovascular Disease. J Inflamm Res. (2021) 14:2647–66. doi: 10.2147/JIR.S308177

15. Jia C, Chen H, Zhang J, Zhou K, Zhuge Y, Niu C, et al. Role of pyroptosis in cardiovascular diseases. Int Immunopharmacol. (2019) 71:311–8. doi: 10.1016/j.intimp.2018.12.028

16. Xia S, Hollingsworth LR, Wu H. Mechanism and regulation of gasdermin-mediated cell death. Cold Spring Harb Perspect Biol. (2020) 12. doi: 10.1101/cshperspect.a036400

17. Zeng C, Wang R, Tan H. Role of pyroptosis in cardiovascular diseases and its therapeutic implications. Int J Biol Sci. (2019) 15:1345–57. doi: 10.7150/ijbs.35568

18. Brennan MA, Cookson BT. Salmonella Induces Macrophage Death by Caspase-1-Dependent Necrosis. Mol Microbiol. (2000) 38. doi: 10.1046/j.1365-2958.2000.02103.x

19. Cookson BT, Brennan MA. Pro-Inflammatory Programmed Cell Death. Trends in Microbiol. (2001) 9. doi: 10.1016/S0966-842X(00)01936-3

20. Kesavardhana S, Malireddi RKS, Kanneganti TD. Caspases in cell death, inflammation, and pyroptosis. Annu Rev Immunol. (2020) 38:567–95. doi: 10.1146/annurev-immunol-073119-071199

21. Wang Q, Wu J, Zeng Y, Chen K, Wang C, Yang S, et al. Pyroptosis: a pro-inflammatory type of cell death in cardiovascular disease. Clin Chim Acta. (2020) 510:62–72. doi: 10.1016/j.cca.2020.06.044

22. Park YH, Wood G, Kastner DL, Chae JJ. Pyrin inflammasome activation and rhoa signaling in the autoinflammatory diseases Fmf and Hids. Nat Immunol. (2016) 17:914–21. doi: 10.1038/ni.3457

23. Gao W, Yang J, Liu W, Wang Y, Shao F. Site-specific phosphorylation and microtubule dynamics control pyrin inflammasome activation. Proc Natl Acad Sci U S A. (2016) 113:E4857–66. doi: 10.1073/pnas.1601700113

24. de Torre-Minguela C, Mesa Del Castillo P, Pelegrín P. The Nlrp3 and Pyrin inflammasomes: implications in the pathophysiology of autoinflammatory diseases. Front Immunol. (2017) 8:43. doi: 10.3389/fimmu.2017.00043

25. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, et al. The Aim2 inflammasome is essential for host defense against cytolsic bacteria and DNA viruses. Nat Immunol. (2010) 11:395–402. doi: 10.1038/ni.1864

26. Heilig R, Broz P. Function and mechanism of the pyrin inflammasome. Eur J Immunol. (2018) 48:230–8. doi: 10.1002/eji.201749647

27. Wu J, Dong E, Zhang Y, Xiao H. The role of the inflammasome in heart failure. Front Physiol. (2021) 12:709703. doi: 10.3389/fphys.2021.709703

28. Corey R, Teresa F, Lindsay M, Diana A, Gino C, S AE. Cleavage of Dfnα by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. Nature Commun. (2017) 8. doi: 10.1038/ncomms14128

AUTHOR CONTRIBUTIONS

RC, WX, and SS conceived and designed the study. YZ and YL involved in a database search extracted the data. QS, YH, and YL analyzed the data and wrote the manuscript. YH polished the English. HW and YH revised the manuscript. All authors listed approved it for publication.

FUNDING

This work was supported by the National Natural Science Foundation of China (Grant Nos. 81904189 and 82074409).

ACKNOWLEDGMENTS

We thank Ruotong Chai, for editing the English text of a draft of this manuscript.
Shi H, Wang Y, Li X, Zhan X, Tang M, Fina M, et al. Nlrp3

Wandel MP, Kim BH, Park ES, Boyle KB, Nayak K, Lagrange

Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. Inflammasome-

Ding J, Wang K, Liu W, She Y, Sun Q, Shi J, et al. Pore-forming act ivity and

Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

Rathinam VA, Vanaja SK, Waggoner L, Sokolovska A, Becker C, Stuart LM, et al. Trif licenses caspase-11-dependent Nlrp3

Boucher D, Monteleone M, Coll RC, Chen KW, Ross CM, Teo JJ, et al. Caspase-1 self-cleavage is an intrinsic mechanism to

Chai et al. Pyroptosis in Cardiac Remodeling

Frontiers in Cardiovascular Medicine | www.frontiersin.org

April 2022 | Volume 9 | Article 870924

485:69–75. doi: 10.1016/j.bbrc.2017.02.021

59. Li R, Zhu S, Nlrp4 inflammasome. Aliment Pharmacol Ther. (2013) 37:1222–32. doi: 10.1111/j.1365-2036.2012.05099.x

58. Omura S, Nakamura S, Fujisawa M, Muto M. Nfr4, an nlrp4 inflammasome activator, accelerates myocardial fibrosis and

57. Shen C, Lu A, Xie W, Ruan J, Negro R, Egelman EH, et al. Molecular mechanism of Nlrp6 inflammasome assembly and

56. Alu A, Han X, Ma X, Wu M, Wei Y, Wei X. The role of

55. Johnson DC, Okondo MC, Orth EL, Rao SD, Huang HC, Ball DP, et al. Dpp8/9 inhibitors activate the card8 inflammasome in

54. Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of

53. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. (2016) 16:407–20. doi: 10.1038/nr.2016.58

52. Faustin B, Lartigue L, Bruey JM, Luciano F, Sergienko E, Bailly-Maitre B, et al. Reconstituted Nalp1 inflammasome reveals two-step mechanism of caspase-

51. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and

50. Taabaazuing CY, Griswold AR, Bachovchin DA. The Nlrp1 and Card8 inflammasomes. Immunol Rev. (2020) 297:13–25. doi: 10.1111/imr.12884

49. Schroder K, Tschopp J. The inflammasomes. Cell. (2010) 140:821–32. doi: 10.1016/j.cell.2010.01.040

48. Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of

47. Rathinam VA, Vanaja SK, Waggoner L, Sokolovska A, Becker C, Stuart LM, et al. Trif licenses caspase-11-dependent Nlrp3

46. Rathinam VA, Vanaja SK, Waggoner L, Sokolovska A, Becker C, Stuart LM, et al. Trif licenses caspase-11-dependent Nlrp3

45. Wandel MP, Kim BH, Park ES, Boyle KB, Nayak K, Lagrange

44. Shi H, Wang Y, Li X, Zhan X, Tang M, Fina M, et al. Nlrp3

43. He Y, Zeng MY, Yang D, Motro B, Núñez G. Nek7 Is an essential mediator

42. Alu A, Han X, Ma X, Wu M, Wei Y, Wei X. The role of

41. Kelley N, Jeltema D, Duan Y, He Y. The Nlrp3 inflammasome: an

40. Zheng X, Zhong T, Ma Y, Wan X, Qin A, Yao B, et al. Bnip3 mediates

39. Wandel MP, Kim BH, Park ES, Boyle KB, Nayak K, Lagrange

38. Wandel MP, Kim BH, Park ES, Boyle KB, Nayak K, Lagrange

37. Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. Inflammasome-

36. Ding J, Wang K, Liu W, She Y, Sun Q, Shi J, et al. Pore-forming activity and

35. Boucher D, Monteleone M, Coll RC, Chen KW, Ross CM, Teo JJ, et al. Caspase-1 self-cleavage is an intrinsic mechanism to

34. Tavakoli Dargani Z, Singla DK. Bnp-7 attenuates inflammation-induced

33. Boucher D, Monteleone M, Coll RC, Chen KW, Ross CM, Teo JJ, et al. Caspase-1 self-cleavage is an intrinsic mechanism to

32. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

31. Boucher D, Monteleone M, Coll RC, Chen KW, Ross CM, Teo JJ, et al. Caspase-1 self-cleavage is an intrinsic mechanism to

30. Bertheloot D, Latz E, Franklin BS. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol Immunol. (2021) 18:1106–

29. Yüpeng W, Wengqin G, Xiaoyan S, Jingjin D, Wang L, Huabin H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. (2017) 547. doi: 10.1038/nature22393

28. Wang X, Zhu X, Yuan S, Wen S, Liu X, Wang C, et al. Tlr4/Nf-β signaling

27. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

26. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

25. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

24. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

23. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

22. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

21. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

20. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

19. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

18. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

17. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

16. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

15. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

14. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

13. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

12. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

11. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

10. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

9. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

8. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

7. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

6. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

5. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

4. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

3. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

2. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

1. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

10. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

9. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

8. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

7. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

6. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

5. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

4. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

3. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

2. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of

1. Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of
to treat cardiovascular fibrosis. *Pharmacol Ther.* (2020) 209:107511. doi: 10.1016/j.pharmthera.2020.107511

73. Zhang X, Qu H, Yang T, Kong X, Zhou H. Regulation and functions of Nlrp3 inflammasome in cardiac fibrosis: current knowledge and clinical significance. *Biomed Phamacother.* (2021) 134:112219. doi: 10.1016/j.biopharm.2021.112219

74. Cheng JM, Akkerhuis KM, Batten LC, van Vark LC, Hillege HL, Paulus WJ, et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. *Eur J Heart Fail.* (2013) 15:1350–62. doi: 10.1093/euhr/hft106

75. Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. *Nat Rev Cardiol.* (2018) 15:387–407. doi: 10.1038/s41569-018-0007-y

76. Tham YK, Bernardo BC, Ooi JY, Weeks KL, McMullen JR. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. *Arch Toxicol.* (2015) 89:1401–38. doi: 10.1007/s00204-015-1477-x

77. Zeng C, Duan F, Hu J, Luo B, Huang B, Lou X, et al. Nlrp3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. *Redox Biol.* (2020) 34:101523. doi: 10.1016/j.redox.2020.101523

78. Bai Y, Sun X, Chu Q, Li A, Qin Y, Li Y, et al. Caspase-1 regulates ang II-induced cardiomyocyte hypertrophy via upregulation of IL-1β. *Biosci Rep.* (2018) 38. doi: 10.1042/BSR20171438

79. Yang X, Pan L, Zhao S, Dai F, Chao M, Jiang H, et al. S-nitrosylation of Muscle Lim Protein (Mlp) facilitates myocardial hypertrophy through Tlr3 (s Toll-like receptor 3-mediated) Rnd3 (Receptor-Interacting Protein 3) and Nlrp3 (Nod-like receptor pyrin domain containing 3) inflammasome activation. *Circulation.* (2020) 141:984–1000. doi: 10.1161/CIRCULATIONAHA.119.042336

80. Yoshida T, Friehs I, Mummidi S, del Nido PJ, Addulnour-Nakhou l S, Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. *Nat Rev Cardiol.* (2018) 15:387–407. doi: 10.1038/s41569-018-0007-y

81. Tham YK, Bernardo BC, Ooi JY, Weeks KL, McMullen JR. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. *Arch Toxicol.* (2015) 89:1401–38. doi: 10.1007/s00204-015-1477-x

82. Zhu YF, Wang R, Chen W, Cao Y, Li LP, Chen X. Mir-133a-containing 3) inflammasome activation. *Int J Mol Cell Cardiol.* (2018) 107:107511. doi: 10.1016/j.pharmthera.2020.107511

83. Mao Q, Liang XL, Zhang CL, Pang YH, Lu YX. Lncrna Klf3-As1 in non-ischemic dilated cardiomyopathy. *Heart Fail Rev.* (2019) 24:7101–13. doi: 10.1007/s10741-019-09900-0

84. Li C, Song H, Chen C, Shen Z, Zhang Q, Liu D, et al. Lncrna PVT1 knockdown ameliorates myocardial ischemia/reperfusion damage via suppressing gsdemr D-mediated pyroptosis in cardiomyocytes. *Front Cardiovasc Med.* (2021) 8:747802. doi: 10.3389/fcvm.2021.747802

85. Wang L, Wu H, Dong S, Li R, Chu Y, Wang N, et al. Beclin1 controls caspase-4 inflammation and pyroptosis in mouse myocardial reperfusion-injury macrovascular injury. *Cell Commun Signal.* (2021) 19:107. doi: 10.1186/s12964-021-00786-z

86. Zhu Y, Wang Y, Guo H, Wu Q, Hu Y. Irf2 contributes to myocardial infarction via regulation of gsdmd induced pyroptosis. *Mol Med Rep.* (2022) 25. doi: 10.3892/mmr.2021.12556

87. Li C, Song H, Chen C, Shen Z, Zhang Q, Liu D, et al. Lncrna PVT1 knockdown ameliorates myocardial ischemia/reperfusion damage via suppressing gsdemr D-mediated pyroptosis in cardiomyocytes. *Front Cardiovasc Med.* (2021) 8:747802. doi: 10.3389/fcvm.2021.747802

88. Chen L, Yin Z, Qin X, Zhuo X, Chen X, Ding G, et al. Cd74 Ablation rescues type 2 diabetes mellitus-induced cardiac remodeling and contractile dysfunction through pyroptosis-evoked regulation of ferroptosis. *Pharmacol Res.* (2022) 176:106086. doi: 10.1016/j.phrs.2022.106086

89. Amit U, Kain D, Wagner A, Sahu A, Nevo-Caspi Y, Gonen N, et al. New role for interleukin-1 receptor α1 in myocardial homeostasis and heart failure. *J Am Heart Assoc.* (2017) 6. doi: 10.1161/JAHA.116.005108

90. Wang X, Li XL, Qin LJ. The Lncrna Xist/Mir-150-5p/C-Fos axis regulates sepsis-induced myocardial injury via Tnixp-modulated pyroptosis. *Lab Invest.* (2021) 101:1118–29. doi: 10.1038/s41374-021-00067-4

91. Chen L, Yin Z, Qin X, Zhuo X, Chen X, Ding G, et al. Cd74 Ablation rescues type 2 diabetes mellitus-induced cardiac remodeling and contractile dysfunction through pyroptosis-evoked regulation of ferroptosis. *Pharmacol Res.* (2022) 176:106086. doi: 10.1016/j.phrs.2022.106086

92. Gao R, Shi H, Chang S, Gao Y, Li X, Lv C, et al. The selective Nlrp3-inflammasome inhibitor mcc950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. *Int Immunopharmacol.* (2019) 74:105375. doi: 10.1016/j.intimp.2019.04.022

93. Chen A, Chen Z, Zhou Y, Wu Y, Xia Y, Liu D, et al. Rosuvastatin protects against coronary microembolization-induced cardiac injury via inhibiting Nlrp3 inflammasome activation. *Cell Death Dis.* (2021) 12:78. doi: 10.1038/s41419-021-03389-1

94. Zhuang L, Huang L, Shi X, Yang L, Hua F, Ma J, et al. Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via Aplk/Nlrp3 inflammasome pathway. *Aging (Albany NY).* (2020) 12:424720–87. doi: 10.18632/aging.202143

95. Ye B, Chen X, Dai S, Han J, Liang X, Liu S, et al. Emodin alleviates myocardial ischemia-reperfusion injury by inhibiting gsdemr D-mediated pyroptosis in cardiomyocytes. *Drug Des Devel Ther.* (2019) 13:975–86. doi: 10.2147/DDDT.S915412

96. Chen A, Chen Z, Xia Y, Lu D, Yang X, Sun A, et al. Liraglutide attenuates Nlrp3 inflammasome-dependent pyroptosis via regulating Sirt1/Nos4/Ros Pathway in H9c2 cells. *Biochem Biophys Res Commun.* (2018) 499:267–72. doi: 10.1016/j.bbrc.2018.03.142
110. Wang F, Gao Q, Yang J, Wang C, Cao J, Sun J, et al. Artemisinin suppresses myocardial ischemia-reperfusion injury via Nlrp3 inflammasome mechanism. *Mol Cell Biochem.* (2020) 474:171-80. doi: 10.1007/s11010-020-03842-3

111. Gu J, Huang H, Liu C, Jiang B, Li M, Liu L, et al. Pinocembrin inhibited cardiomyocyte pyroptosis against doxorubicin-induced cardiac dysfunction via regulating Nrf2/Sirt3 signaling pathway. *Int Immunopharmacol.* (2021) 95:107533. doi: 10.1016/j.intimp.2021.107533

112. Qu XF, Zhai BZ, Hu WL, Lou MH, Chen YH, Liu YF, et al. Pyrroloquinoline quinone ameliorates diabetic cardiomyopathy by inhibiting the pyroptosis signaling pathway in C57bl/6 mice and Ac16 cells. *Eur J Nutr.* (2022).

113. Lei Z, Luan F, Zhang X, Peng L, Li B, Peng X, et al. Piperazine ferulate protects against cardiac ischemia/reperfusion injury in rat via the suppression of Nlrp3 inflammasome activation and pyroptosis. *Eur J Pharmacol.* (2022) 920:174856. doi: 10.1016/j.ejphar.2022.174856

114. Wu J, Cai W, Du R, Li H, Wang B, Zhou Y, et al. Sevoflurane alleviates myocardial ischemia reperfusion injury by inhibiting p2x7-nlrp3 mediated pyroptosis. *Front Mol Biosci.* (2021) 8:768594. doi: 10.3389/fmolb.2021.768594

115. Diao M, Xu J, Wang J, Zhang M, Wu C, Hu X, et al. Alda-1, an Activator of Aldh2, improves postresuscitation cardiac and neurological outcomes by inhibiting pyroptosis in swine. *Neurochem Res.* (2022) 47:1097–109. doi: 10.1007/s11064-021-03511-x

116. Yang F, Qin Y, Lv J, Wang Y, Che H, Chen X, et al. Silencing long non-coding RNA Kcnq1ot1 alleviates pyroptosis and fibrosis in diabetic cardiomyopathy. *Cell Death Dis.* (2018) 9:1000. doi: 10.1038/s41419-018-1029-4

117. Cao L, Wang Y, Wang Y, Lv F, Liu L, Li Z. Resolvin D2 suppresses Nlrp3 inflammasome by promoting autophagy in macrophages. *Exp Ther Med.* (2021) 22:1222. doi: 10.3892/etm.2021.10656

118. Liu Y, Guo X, Zhang J, Han X, Wang H, Du F, et al. Protective effects of the soluble receptor for advanced glycation end-products on pyroptosis during myocardial ischemia-reperfusion. *Oxid Med Cell Longev.* (2021) 2021:9570971. doi: 10.1155/2021/9570971

119. Wang X, Li Y, Li J, Li S, Wang F. Mechanism of Mettl3-mediated M (6)a modification in cardiomyocyte pyroptosis and myocardial ischemia-reperfusion injury. *Cardiovasc Drugs Ther.* (2022). doi: 10.1007/s10557-021-07300-0

120. Lee CY, Lee S, Jeong S, Lee J, Seo HH, Shin S, et al. Suppressing pyroptosis augments post-transplant survival of stem cells and cardiac function following ischemic injury. *Int J Mol Sci.* (2021) 22. doi: 10.3390/ijms22157946

121. Nie C, Zou R, Pan S, A R, Guo Y, Yang H, et al. Hydrogen Gas Inhalation Ameliorates Cardiac Remodellng and Fibrosis by Regulating Nlrp3 Inflammasome in Myocardial Infarction Rats. *J Cell Mol Med.* (2021) 25:8997–9010. doi: 10.1111/jcmm.16863

122. Xu J, Zhang M, Liu F, Shi L, Jiang X, Chen C, et al. Mesenchymal stem cells alleviate post-resuscitation cardiac and cerebral injuries by inhibiting cell pyroptosis and ferroptosis in a swine model of cardiac arrest. *Front Pharmacol.* (2021) 12:793829. doi: 10.3389/fphar.2021.793829

123. Schirone L, Forte M, Palmerio S, Yee D, Nocella C, Angelini F, et al. A review of the molecular mechanisms underlying the development and progression of cardiac remodeling. *Oxid Med Cell Longev.* (2017) 2017:3920195. doi: 10.1155/2017/3920195

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chai, Xue, Shi, Zhou, Du, Li, Song, Wu and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.